CL2018002101A1 - Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización - Google Patents

Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización

Info

Publication number
CL2018002101A1
CL2018002101A1 CL2018002101A CL2018002101A CL2018002101A1 CL 2018002101 A1 CL2018002101 A1 CL 2018002101A1 CL 2018002101 A CL2018002101 A CL 2018002101A CL 2018002101 A CL2018002101 A CL 2018002101A CL 2018002101 A1 CL2018002101 A1 CL 2018002101A1
Authority
CL
Chile
Prior art keywords
preparation process
trifluoroacetate
crystalline form
tlr7 agonist
tlr7
Prior art date
Application number
CL2018002101A
Other languages
English (en)
Inventor
Zhaozhong Ding
Fei Sun
Ling Yang
Yinghu Hu
Yilong Zhou
Zheng Wang
Rui Zhao
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CL2018002101A1 publication Critical patent/CL2018002101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN TRIFLUOROACETATO DE 2–BUTOXI–7– (4–(PIRROLIDIN–1–ILMETIL)BENCIL)–5H–PIRROLO[3,2–D]PIRIMIDIN–4–AMINA COMO AGONISTA DE TLR7 (FÓRMULA I), LA FORMA CRISTALINA B, EL PROCESO DE PREPARACIÓN Y SU UTILIZACIÓN.
CL2018002101A 2016-02-05 2018-08-03 Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización CL2018002101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610081899.3A CN107043377A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途

Publications (1)

Publication Number Publication Date
CL2018002101A1 true CL2018002101A1 (es) 2018-12-07

Family

ID=59500539

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002101A CL2018002101A1 (es) 2016-02-05 2018-08-03 Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización

Country Status (23)

Country Link
US (1) US10683296B2 (es)
EP (1) EP3412674B1 (es)
JP (1) JP6877450B2 (es)
KR (1) KR102393281B1 (es)
CN (2) CN107043377A (es)
AR (1) AR107550A1 (es)
AU (1) AU2017214135B2 (es)
BR (1) BR112018015878A2 (es)
CA (1) CA3013521C (es)
CL (1) CL2018002101A1 (es)
DK (1) DK3412674T3 (es)
EA (1) EA037048B1 (es)
ES (1) ES2834304T3 (es)
HK (1) HK1259182A1 (es)
HU (1) HUE052210T2 (es)
IL (1) IL260981B (es)
MX (1) MX2018009503A (es)
NZ (1) NZ745023A (es)
PH (1) PH12018501641A1 (es)
SG (1) SG11201806688QA (es)
TW (1) TWI778952B (es)
UA (1) UA121276C2 (es)
WO (1) WO2017133687A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11999750B2 (en) 2023-01-11 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN112105620A (zh) * 2018-05-25 2020-12-18 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
EP4194006A1 (en) 2020-08-04 2023-06-14 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
US9139590B2 (en) * 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) * 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
CN104837840B (zh) * 2012-10-10 2017-08-08 爱尔兰詹森科学公司 用于治疗病毒感染及其他疾病的吡咯并[3，2‑d]嘧啶衍生物
CN104780924B (zh) * 2012-11-20 2016-09-14 葛兰素史克有限责任公司 干扰素诱导剂化合物
CN106232603B (zh) * 2014-05-01 2019-07-05 诺华股份有限公司 作为toll-样受体7激动剂的化合物和组合物
EA032487B1 (ru) * 2014-05-01 2019-06-28 Новартис Аг Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
US9962388B2 (en) 2014-08-15 2018-05-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as TLR7 agonist
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11999750B2 (en) 2023-01-11 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Also Published As

Publication number Publication date
UA121276C2 (uk) 2020-04-27
WO2017133687A1 (zh) 2017-08-10
EP3412674B1 (en) 2020-09-16
KR20180104118A (ko) 2018-09-19
BR112018015878A2 (pt) 2018-12-26
PH12018501641B1 (en) 2019-06-03
EA037048B1 (ru) 2021-01-29
KR102393281B1 (ko) 2022-05-02
EP3412674A4 (en) 2019-07-17
DK3412674T3 (da) 2020-11-09
TWI778952B (zh) 2022-10-01
CA3013521C (en) 2022-07-12
CN107043377A (zh) 2017-08-15
AU2017214135B2 (en) 2020-08-13
MX2018009503A (es) 2018-12-11
ES2834304T3 (es) 2021-06-17
AU2017214135A1 (en) 2018-08-23
JP6877450B2 (ja) 2021-05-26
PH12018501641A1 (en) 2019-06-03
EA201891772A1 (ru) 2019-01-31
NZ745023A (en) 2022-09-30
US10683296B2 (en) 2020-06-16
JP2019504103A (ja) 2019-02-14
CN108602833B (zh) 2020-07-28
US20190031666A1 (en) 2019-01-31
HK1259182A1 (zh) 2019-11-29
SG11201806688QA (en) 2018-09-27
AR107550A1 (es) 2018-05-09
IL260981B (en) 2022-05-01
EP3412674A1 (en) 2018-12-12
CA3013521A1 (en) 2017-08-10
TW201728591A (zh) 2017-08-16
CN108602833A (zh) 2018-09-28
HUE052210T2 (hu) 2021-04-28

Similar Documents

Publication Publication Date Title
CL2018002101A1 (es) Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización
BR112019000696A2 (pt) antagonistas de tlr7/8 e uso dos mesmos
IL247923B (en) 4-substituted nucleotide derivatives as HIV reverse transcriptase inhibitors
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
CL2018002092A1 (es) Forma cristalina a de agonista de tlr7, su proceso de preparación y uso
WO2016011390A8 (en) Irak4 inhibiting agents
BR112018017091A2 (pt) profármacos de pth
MA39749A (fr) Dérivés de pipéridine-dione
PH12018500071A1 (en) Plinabulin compositions
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
NZ727392A (en) Methods of preparing substituted nucleotide analogs
IL262650B (en) Aqueous agricultural preparation with improved spray drift performance
CL2018002094A1 (es) Un proceso para preparar compuesto de pirrolo[3,2–d]pirimidina y su intermediario
EP3524721A4 (en) FLAME-RESISTANT KNITWEAR
PH12018500903A1 (en) Pyranodipyridine compound
MX2017014549A (es) Farmacos precursores de oxabicicloheptanos.
MX2015008829A (es) Momelotinib deuterado.
FI20145190A (fi) Kiinnitin lisävarusteen kiinnittämiseksi aseeseen
NZ725165A (en) Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors
WO2016068640A3 (ko) 헤테로고리 화합물 및 이를 이용한 유기발광소자
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
EP3302113A4 (en) Clothing articles especially useful for aquatic activities
MX2016016127A (es) Formas cristalinas.
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma